Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone617-374-7580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.52 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines Corp (NASDAQ:BPMC) released its quarterly earnings data on Tuesday, February, 26th. The biotechnology company reported ($1.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.76) by $0.07. The biotechnology company earned $1.03 million during the quarter, compared to analysts' expectations of $1.77 million. Blueprint Medicines had a negative return on equity of 46.58% and a negative net margin of 531.53%. The company's revenue was down 36.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.23) EPS. View Blueprint Medicines' Earnings History.
When is Blueprint Medicines' next earnings date?
What price target have analysts set for BPMC?
5 brokers have issued 1 year target prices for Blueprint Medicines' shares. Their predictions range from $102.00 to $105.00. On average, they anticipate Blueprint Medicines' share price to reach $103.25 in the next twelve months. This suggests a possible upside of 24.3% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.
What is the consensus analysts' recommendation for Blueprint Medicines?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.
Has Blueprint Medicines been receiving favorable news coverage?
Press coverage about BPMC stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Blueprint Medicines earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include ABIOMED (ABMD), Ono Pharmaceutical (OPHLF), Cardinal Health (CAH), Universal Health Services (UHS), Cooper Companies (COO), Mylan (MYL), Merck KGaA (MKGAF), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), DexCom (DXCM), Sunny Optical Technology (Group) (SNPTF), Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), GRIFOLS S A/S (GRFS) and SYSMEX CORP/ADR (SSMXY).
What other stocks do shareholders of Blueprint Medicines own?
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
- Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
- Mr. Michael Landsittel, Chief Financial Officer (Age 47)
- Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
- Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.02%), BlackRock Inc. (7.85%), Partner Fund Management L.P. (3.35%), Hillhouse Capital Advisors Ltd. (3.26%), Perceptive Advisors LLC (1.95%) and Norges Bank (1.80%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.
Which major investors are selling Blueprint Medicines stock?
BPMC stock was sold by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Perceptive Advisors LLC, Citigroup Inc., Millennium Management LLC, Jennison Associates LLC, Barclays PLC, Tekla Capital Management LLC and Eagle Asset Management Inc.. Company insiders that have sold Blueprint Medicines company stock in the last year include George Demetri, Jeffrey W Albers, Kate Haviland and Marion Dorsch. View Insider Buying and Selling for Blueprint Medicines.
Which major investors are buying Blueprint Medicines stock?
BPMC stock was purchased by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., Norges Bank, Foresite Capital Management III LLC, American Century Companies Inc., Lord Abbett & CO. LLC, Artal Group S.A., Two Sigma Investments LP and Westfield Capital Management Co. LP. View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $83.05.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $3.66 billion and generates $44.52 million in revenue each year. The biotechnology company earns $-236,640,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis.
What is Blueprint Medicines' official website?
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
